These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25200488)

  • 1. [Batch release of immunoglobulin and monoclonal antibody products].
    Gross S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1185-7. PubMed ID: 25200488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Testing of vaccines. The challenge of testing complex combination vaccines].
    Merkle A; Lechner H; Oppling V; Meyer H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1188-92. PubMed ID: 25204275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Testing of medicinal products produced from pooled plasma].
    Unkelbach U; Hunfeld A; Breitner-Ruddock S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1181-4. PubMed ID: 25213735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Official experimental testing of biomedical products. Regulatory frame and importance of for quality, safety and efficacy].
    Vieths S; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1133-8. PubMed ID: 25123139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Official testing of immunological veterinary medicinal products].
    Jungbäck C; Motitschke A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1193-7. PubMed ID: 25168840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies for use in man: current regulatory situation in the Federal Republic of Germany.
    Haase M
    Dev Biol Stand; 1990; 71():213-20. PubMed ID: 2205526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Governmental batch sample testing of allergen products].
    Bartel D; Führer F; Vieths S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):358-62. PubMed ID: 22373849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Viral safety of biological medicinal products].
    Stühler A; Blümel J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Official batch control of influenza vaccines: Is it still useful?
    Kretzschmar E; Muckenfuss H; Pfleiderer M
    Vaccine; 2018 Apr; 36(17):2364-2370. PubMed ID: 29580639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.
    Tierney R; Hockley J; Rigsby P; Terao E; Daas A; Buchheit KH; Sesardic D
    Pharmeur Bio Sci Notes; 2011 Jun; 2011(1):1-26. PubMed ID: 21619853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The network of official medicines control laboratories].
    Buchheit KH; Wanko R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
    Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety monitoring of cell-based medicinal products (CBMPs)].
    Funk MB; Frech M; Spranger R; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of product batches (before and after registration). The German approach.
    Jungbäck C
    Dev Biol Stand; 1992; 79():171-4. PubMed ID: 1286753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allergens for specific immunotherapy: authorization and quality criteria of the Paul-Ehrlich-Institut].
    May S; Kaul S; Schröder C; Vieths S
    Hautarzt; 2006 Oct; 57(10):867-74. PubMed ID: 16977441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experiences and recommendations of the German Federal Institute for Drugs and Medical Devices (BfArM) concerning clinical investigation of medical devices and the evaluation of serious adverse events (SAE)].
    Renisch B; Lauer W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Dec; 57(12):1368-75. PubMed ID: 25376539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety of high risk in vitro diagnostic medical devices : international and national measures].
    Halbauer J; Siekmeier R; Funk M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):610-8. PubMed ID: 19421725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of reagents for infection testing: results of the market surveillance by the Federal Institute for Drugs and Medicinal Devices until end 2006.
    Siekmeier R; Halbauer J; Mientus W; Wetzel D
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():629-43. PubMed ID: 19218690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Batch testing as an essential pillar of the supply of safe and effective vaccines].
    Sediri-Schön H; Lange J; Grabski E; Wagner R; Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1244-1250. PubMed ID: 36264321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.